253 related articles for article (PubMed ID: 28532503)
41. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer.
Yu Y; Tan Y; Xie C; Hu Q; Ouyang J; Chen Y; Gu Y; Li A; Lu N; He Z; Yang Y; Chen K; Ma J; Li C; Ma M; Li X; Zhang R; Zhong H; Ou Q; Zhang Y; He Y; Li G; Wu Z; Su F; Song E; Yao H
JAMA Netw Open; 2020 Dec; 3(12):e2028086. PubMed ID: 33289845
[TBL] [Abstract][Full Text] [Related]
42. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
43. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
[TBL] [Abstract][Full Text] [Related]
44. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
45. Analysis of Breast Cancer Family History, Estrogen Receptor Status, and Breast Cancer Outcomes in Sweden.
Zhang Y; Wang QL; Zeng E; He W; Czene K
JAMA Netw Open; 2023 Jun; 6(6):e2318053. PubMed ID: 37310740
[TBL] [Abstract][Full Text] [Related]
46. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Albain KS; Barlow WE; Shak S; Hortobagyi GN; Livingston RB; Yeh IT; Ravdin P; Bugarini R; Baehner FL; Davidson NE; Sledge GW; Winer EP; Hudis C; Ingle JN; Perez EA; Pritchard KI; Shepherd L; Gralow JR; Yoshizawa C; Allred DC; Osborne CK; Hayes DF;
Lancet Oncol; 2010 Jan; 11(1):55-65. PubMed ID: 20005174
[TBL] [Abstract][Full Text] [Related]
47. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Albain KS; Green S; LeBlanc M; Rivkin S; O'Sullivan J; Osborne CK
Breast Cancer Res Treat; 1992; 22(3):273-84. PubMed ID: 1391993
[TBL] [Abstract][Full Text] [Related]
48. Prognostic models for identifying risk of poor outcome in people with acute ankle sprains: the SPRAINED development and external validation study.
Keene DJ; Schlüssel MM; Thompson J; Hagan DA; Williams MA; Byrne C; Goodacre S; Cooke M; Gwilym S; Hormbrey P; Bostock J; Haywood K; Wilson D; Collins GS; Lamb SE
Health Technol Assess; 2018 Nov; 22(64):1-112. PubMed ID: 30474592
[TBL] [Abstract][Full Text] [Related]
49. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
50. Is age at diagnosis an independent prognostic factor for survival following breast cancer?
Jayasinghe UW; Taylor R; Boyages J
ANZ J Surg; 2005 Sep; 75(9):762-7. PubMed ID: 16173989
[TBL] [Abstract][Full Text] [Related]
51. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
[TBL] [Abstract][Full Text] [Related]
52. Prognostic models of survival in patients with advanced incurable cancer: the PiPS2 observational study.
Stone P; Kalpakidou A; Todd C; Griffiths J; Keeley V; Spencer K; Buckle P; Finlay DA; Vickerstaff V; Omar RZ
Health Technol Assess; 2021 May; 25(28):1-118. PubMed ID: 34018486
[TBL] [Abstract][Full Text] [Related]
53. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.
Kiba T; Inamoto T; Nishimura T; Ueno M; Yanagihara K; Teramukai S; Kato H; Toi M; Fukushima M
BMC Cancer; 2008 Nov; 8():323. PubMed ID: 18990247
[TBL] [Abstract][Full Text] [Related]
54. Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis.
Holm J; Li J; Darabi H; Eklund M; Eriksson M; Humphreys K; Hall P; Czene K
J Clin Oncol; 2016 Jan; 34(3):251-8. PubMed ID: 26628467
[TBL] [Abstract][Full Text] [Related]
55. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
56. Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer.
Lischka A; Doberstein N; Freitag-Wolf S; Koçak A; Gemoll T; Heselmeyer-Haddad K; Ried T; Auer G; Habermann JK
Clin Cancer Res; 2020 Sep; 26(17):4606-4615. PubMed ID: 32522886
[TBL] [Abstract][Full Text] [Related]
57. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
Johansson ALV; Trewin CB; Fredriksson I; Reinertsen KV; Russnes H; Ursin G
Breast Cancer Res; 2021 Feb; 23(1):17. PubMed ID: 33526044
[TBL] [Abstract][Full Text] [Related]
58. Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.
Stabellini N; Cao L; Towe CW; Miller ME; Sousa-Santos AH; Amin AL; Montero AJ
J Natl Compr Canc Netw; 2023 Oct; 21(10):1011-1019.e6. PubMed ID: 37856198
[TBL] [Abstract][Full Text] [Related]
59. Nodal ratio of positive to excised nodes, but not number of positive lymph nodes is better to predict group to avoid chemotherapy among postmenopausal ER-positive, lymph node-positive T1-T2 breast cancer patients.
Jia XQ; Hong Q; Cheng JY; Li JW; Wang YJ; Mo M; Shao ZM; Shen ZZ; Liu GY
J Cancer Res Ther; 2015; 11(4):740-5. PubMed ID: 26881511
[TBL] [Abstract][Full Text] [Related]
60. Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
Bundred NJ; Prasad R; Morris J; Knox WF; Byrne G; Cheung S; Wilson M; Lawrence G
Breast Cancer Res Treat; 2013 Apr; 138(2):359-68. PubMed ID: 21744241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
